J&J (JNJ) Q1 Revenue Surges 10% to $24.1B, Beats Analyst Estimates

Johnson & Johnson (JNJ) reported first-quarter revenue of $24.1 billion, a nearly 10% increase from the previous year, surpassing analyst estimates of $23.6 billion. Adjusted earnings were $2.70 per share, exceeding the consensus estimate of $2.66. Key drug sales included $4 billion for Darzalex and $1.6 billion for Tremfya, both outperforming projections, while Stelara sales fell 60% to $656 million. JNJ raised its full-year revenue forecast to a midpoint of approximately $100.8 billion, slightly above Wall Street's estimate of $100.6 billion.